ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Eisai and Biogen win FDA approval for latest Alzheimer's drug

U.S. authorization of Leqembi follows setbacks with Aduhelm

An Alzheimer's patient receives an intravenous infusion of Aduhelm at a hospital in Providence, Rhode Island. Eisai's follow-up dementia drug lecanemab is also administered intravenously.   © Reuters

TOKYO/NEW YORK -- The U.S. Food and Drug Administration on Friday approved a treatment for Alzheimer's disease developed by Japanese pharmaceutical company Eisai and American partner Biogen.

Clinical trials showed that lecanemab, which will be marketed as Leqembi, slows cognitive decline for patients in the early stages of Alzheimer's.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more